AR050297A1 - Hidantoinas sustituidas - Google Patents

Hidantoinas sustituidas

Info

Publication number
AR050297A1
AR050297A1 ARP050103440A ARP050103440A AR050297A1 AR 050297 A1 AR050297 A1 AR 050297A1 AR P050103440 A ARP050103440 A AR P050103440A AR P050103440 A ARP050103440 A AR P050103440A AR 050297 A1 AR050297 A1 AR 050297A1
Authority
AR
Argentina
Prior art keywords
group
substituted
alkyl
alkoxy
compounds
Prior art date
Application number
ARP050103440A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR050297A1 publication Critical patent/AR050297A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Los compuestos de la presente son utiles para tratar enfermedades caracterizadas por la hiperactividad de la MEK. Por consiguiente, los compuestos son utiles para el tratamiento de enfermedades, tales como el cáncer, trastornos cognitivos y del SNC y enfermedades inflamatorias/autoinmunes. Reivindicacion 1: Un compuesto de la formula (1) en la que: R1 se elige entre el conjunto formado por un grupo arilo sustituido o sin sustituir y un grupo heteroarilo sustituido o sin sustituir; R2 es H; R3 es un grupo alquilo; R4 se elige entre el grupo formado por un grupo arilo sustituido o sin sustituir, hidroxilo, alcoxi, alcoxi sustituido y un grupo heteroarilo o alquilo sustituido o sin sustituir; R5 se elige entre el grupo formado por COOR, COR, CON(R7)2, CHOHR y S(O)nR, en los que n es 0-2 y en los que R es alquilo o alquilo sustituido por un grupo alcoxi; y R6 y R7 se eligen entre H y un grupo alquilo, opcionalmente en forma de sus racematos, sus enantiomeros, sus diastereoisomeros o mezclas de los mismos, o las sales, ésteres o profármacos farmacéuticamente aceptables del mismo.
ARP050103440A 2004-08-17 2005-08-16 Hidantoinas sustituidas AR050297A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US68299705P 2005-05-20 2005-05-20

Publications (1)

Publication Number Publication Date
AR050297A1 true AR050297A1 (es) 2006-10-11

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103440A AR050297A1 (es) 2004-08-17 2005-08-16 Hidantoinas sustituidas

Country Status (16)

Country Link
US (1) US7427635B2 (es)
EP (1) EP1781649B1 (es)
JP (1) JP4927733B2 (es)
KR (2) KR20090006885A (es)
AR (1) AR050297A1 (es)
AT (1) ATE404556T1 (es)
AU (1) AU2005274390B2 (es)
BR (1) BRPI0514515A (es)
CA (1) CA2576599A1 (es)
DE (1) DE602005008986D1 (es)
ES (1) ES2313389T3 (es)
MX (1) MX2007001846A (es)
PL (1) PL1781649T3 (es)
RU (1) RU2383542C2 (es)
TW (1) TW200621764A (es)
WO (1) WO2006018188A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
WO2009021887A1 (en) 2007-08-16 2009-02-19 F. Hoffmann-La Roche Ag Substituted hydantoins
KR20100086503A (ko) 2007-12-20 2010-07-30 에프. 호프만-라 로슈 아게 Ｍｅｋ 키나아제 저해제로서의 치환된 히단토인
DK2959900T3 (en) 2008-06-16 2017-06-26 Univ Tennessee Res Found CONNECTION TO TREATMENT OF CANCER
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
ES2714875T3 (es) 2010-03-09 2019-05-30 Dana Farber Cancer Inst Inc Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
MX2012012460A (es) 2010-04-28 2012-11-21 Bayer Cropscience Ag Derivados de cetoheteroarilpiperidina y de cetoheteroarilpiperazin a como fungicidas.
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA3106855A1 (en) * 2018-09-17 2020-03-26 Yungjin Pharm. Co., Ltd. Thiazole derivatives and pharmaceutically acceptable salts thereof
US20230095520A1 (en) * 2020-03-13 2023-03-30 Yungjin Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating cancer comprising azole derivatives or pharmaceutically acceptable salt thereof
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
DK1280801T3 (da) * 2000-05-03 2006-01-23 Hoffmann La Roche Hydantoinholdige glucokinaseaktivatorer
GEP20105095B (en) * 2001-07-19 2010-10-25 Pfizer Italia Srl Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
MX2007001846A (es) 2007-03-28
ATE404556T1 (de) 2008-08-15
WO2006018188A3 (en) 2006-05-18
PL1781649T3 (pl) 2009-01-30
TW200621764A (en) 2006-07-01
KR20090006885A (ko) 2009-01-15
WO2006018188A2 (en) 2006-02-23
RU2383542C2 (ru) 2010-03-10
US7427635B2 (en) 2008-09-23
DE602005008986D1 (de) 2008-09-25
JP4927733B2 (ja) 2012-05-09
ES2313389T3 (es) 2009-03-01
BRPI0514515A (pt) 2008-06-10
AU2005274390B2 (en) 2012-01-19
KR100889721B1 (ko) 2009-03-23
JP2008509950A (ja) 2008-04-03
KR20070034635A (ko) 2007-03-28
CA2576599A1 (en) 2006-02-23
AU2005274390A1 (en) 2006-02-23
EP1781649B1 (en) 2008-08-13
EP1781649A2 (en) 2007-05-09
US20060041146A1 (en) 2006-02-23
RU2007109651A (ru) 2008-09-27

Similar Documents

Publication Publication Date Title
AR050297A1 (es) Hidantoinas sustituidas
AR051290A1 (es) Derivados de hidantoina sustituidas
AR046186A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona
AR062387A2 (es) El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR040476A1 (es) N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
CU20090184A7 (es) Compuestos amino-heterocíclicos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR070520A1 (es) Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros.
AR059590A1 (es) Inhibidores de quinasa basados en la hidantoina
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
EA200501658A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
CR6165A (es) Procedimientos e intermedios para preparar compuestos anticancerosos
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
AR054991A1 (es) Pteridinas sustituidas y su uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias
UY28333A1 (es) Inhibidores de caspasa y sus usos.
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
AR054813A1 (es) Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1

Legal Events

Date Code Title Description
FB Suspension of granting procedure